New hope for Tough-to-Treat breast cancer: experimental combo enters human trials
NCT ID NCT05608252
Summary
This study is testing the safety and effectiveness of a new drug, VS-6766, when combined with two existing breast cancer drugs (abemaciclib and fulvestrant). It is for people with advanced HR+/HER2- breast cancer that has worsened despite prior standard treatments. The goal is to see if this three-drug combination can help control the cancer for a longer period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dana Farber Cancer Institite
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Massachusetts General Hospital Cancer Center
WITHDRAWNBoston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.